PLRX Earnings Date: Nov 5, 2026 (Estimated) — Pliant Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is PLRX's next earnings date?
Pliant Therapeutics, Inc. (PLRX) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.37.
How did PLRX do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q2 2026), Pliant Therapeutics, Inc. posted EPS of -$0.36 versus the -$0.34 estimate, a miss of 5.9%. Revenue was $0. The stock's 1-day post-earnings move was +3.9%.
How much does PLRX stock move after earnings?
PLRX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.1% (up or down) in the day after earnings.
About Pliant Therapeutics, Inc.
Pliant Therapeutics, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to discovering, advancing, and bringing to market innovative therapies for fibrotic and related diseases across the United States. Its flagship investigational product, PLN-74809, is an orally administered, small-molecule, dual-selective inhibitor targeting both avß6 and avß1 integrins, which is currently progressing through three distinct Phase 2a clinical trials. The company's pipeline also includes PLN-1474, a small-molecule selective inhibitor of avß1, which has successfully completed its Phase 1 clinical assessment for treating liver fibrosis associated with nonalcoholic steatohepatitis (NASH). Furthermore, Pliant is nurturing two additional integrin-based initiatives in preclinical development: one focused on oncology, and another involving an allosteric agonistic monoclonal antibody designed to act upon an undisclosed integrin receptor for the treatment of various muscular dystrophies, including Duchenne muscular dystrophy. Founded in 2015, Pliant Therapeutics, Inc. maintains its corporate headquarters in South San Francisco, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q2 2026 | -0.34 | -0.36 | -5.88% | $0 | ❌ Miss | +3.88% | +11.65% | +9.71% |
| 2026-05-11 | Q1 2026 | -0.36 | -0.32 | +11.11% | $0 | ✅ Beat | -1.67% | -1.67% | -3.33% |
| 2026-03-11 | Q4 2025 | -0.40 | -0.38 | +5.00% | $0 | ✅ Beat | +6.01% | -3.76% | -3.76% |
| 2025-11-06 | Q3 2025 | -0.53 | -0.43 | +18.87% | $0 | ✅ Beat | +4.58% | +12.42% | -16.34% |
| 2025-03-03 | Q4 2024 | -0.98 | -0.82 | +16.33% | $0 | ✅ Beat | -2.17% | +3.62% | -0.72% |
| 2024-11-07 | Q3 2024 | -0.98 | -0.95 | +3.06% | $0 | ✅ Beat | -1.25% | -15.40% | -2.24% |
| 2024-08-07 | Q2 2024 | -0.85 | -0.92 | -8.24% | $0 | ❌ Miss | -2.23% | -4.86% | +2.63% |
| 2023-08-09 | Q2 2023 | -0.71 | -0.70 | +1.41% | $248,000 | ✅ Beat | +3.30% | -5.39% | -9.52% |
Showing last 8 quarters.